AddLife Q3 report October, 2017

AddLife introduction A leading independent player mainly in the Nordic Life Science market Markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector in the Nordics 32 subsidiaries Labtech and Medtech Net sales SEK 2,276m 2

Our vision AddLife strives to improve people’s lives by being a leading and value adding player within Life Science Sofias kommentar; tycker att du här ska prata om vikten av en tydlig vision som styr organisationen framåt. En vision är inte bara ord och utan vad som ska ange riktningen för verksamheten varje dag. Som koncern är det er uppgift att tydliggöra visionen både internt till medarbetarna och till omvärlden. Det kan bland annat innebära att i all kommunikation knyta an till just visionen. Om du betonar detta när du pratar om den här bilden blir det sedan naturligt för Artur att ta resonemanget vidare. 3

Nordics is our home market Other markets/operations Production plant Key markets 4

Products Advisory services Service and support Trainings Customer offering Products Advisory services Service and support Trainings 5

Two business areas Labtech Products Customers Companies Medtech

Decentralized organization with entrepreneurial business acumen Combine the small company’s… With the large company’s… Flexibility Resources ”Small scale business – large scale wise” Personality Network Effectiveness Sustainability 7

Interim report Q3 2017 8

Highlights Q3 ”Strong summer quarter!” Net Sales SEK 517m (409), +26%, organic, +9% EBITA SEK 44m (31), +39% EBITA-margin 8.5% (7.7) R12 Months Net Sales SEK 2,276 (1,799) +27%, organic, +8% EBITA SEK 231 (155) +49% EBITA-margin 10.1% (8.6) 9

Market update Q3 Positive development especially within research and health care. Stable within diagnostics. Larger product portfolio has enabled larger and more tenders within health care. Streamline warehouse and logistics in Medtech. Developed well in the quarter from health care, diagnostics and research. Somewhat weaker demand still from pharma industry. Developed favourably in research and diagnostics. Slightly weaker in health care. Delay in healthcare and social services reform until 2020 has led to some uncertainty in the market. Continued positive trend in the quarter. High activity in the market from health care, home care and research. Exports developed well for health care and home care. Weaker for advanced instruments mainly in the US. 10

Labtech Comments 11 Organic sales growth of 14% in Q and 10% YTD Acquired sales growth of 9% in Q and 8% YTD Positive development in diagnostics, especially in Finland. Continued high grants to research, especially in Sweden and Norway Still lower activity within pharmaceutical industry in Denmark. Weaker demand than expected for own high-tech instruments. EBITA increase during Q3 by 21%, corresponding to an EBITA-margin of 8.6% (8.6) EBITA increase during YTD by 13%, corresponding to an EBITA-margin of 10.2% (10.8) YoY +21% 11

Medtech Comments 12 Organic sales increase 3% in Q and increase 5% YTD Acquired sales growth of 31% in Q and 29% YTD Activity lower due to summer vacations Increase in underlying demand in all Nordic countries except for Finland. Streamline of warehouse and logistics Positive demand within home care. Krabat AS acquired in Q3 EBITA increased during Q3 by 80% corresponding to an EBITA- margin of 9.8% (7.3) EBITA increased during YTD by 69% corresponding to an EBITA- margin of 9.3% (7.4) YoY +34% 12

Profitability (P/WC) Cash Flow 13 3 months ending 9 months ending (SEKm) 30 Sep 17 30 Sep 16 Profit after financial items 25 22 101 81 Adj. For non cash items 23 19 62 54 Income tax paid -8 -12 -24 -34 Changes in working capital -13 -1 -28 -64 Cash flow from operating activities 27 28 111 37 Net investment in non-current assets -9 -5 -27 -39 Acquisitions and disposals -47 -6 -296 -42 Cash flow from investing activities -56 -11 -323 -81 Dividend paid - -37 -277 Repurchase treasury shares -33 Other financing activities 63 11 290 230 Period´s cash flow -3 4 -124 Return on working capital (P/WC) amounted to 65% (55) Change in P/WC is attributable to the increased EBITA Cash flow from operating activities amounted to SEK 111m (37) Increased operating cash due to higher profit and more efficient working capital management 13

Balance sheet 14

Selected key financial ratios 15

Q & A